Nav: Home

Mount Sinai researchers present results at American Society of Hematology Meeting

December 07, 2015

Icahn School of Medicine at Mount Sinai researchers will present several landmark studies at the 2015 American Society of Hematology (ASH) meeting December 5-8, 2015, in Orlando, including data analysis of newly diagnosed multiple myeloma that revealed insight into key biological processes and deeper understanding of cellular systems and disease mechanisms, and two combination therapy strategies that showed high response rates in patients with difficult-to-treat myeloma.

Highlights of Mount Sinai research at ASH:

Towards a Network-Based Molecular Taxonomy of Newly Diagnosed Multiple Myeloma

Mount Sinai researchers, led by Samir Parekh, MBBS, constructed the first network biology of multiple myeloma based on RNA-sequencing data provided by the Multiple Myeloma Research Foundation (MMRF) and integrated cell mutations data to infer a better model and understanding of newly diagnosed multiple myeloma (MM). Their analysis revealed both known and unknown molecular features yielding valuable insight into key biological processes.

"We created a network model for MM and uncovered agreements between expressed genes and their molecular traits, and incorporating cell mutation data," said Dr. Parekh, Associate Professor of Hematology and Medical Oncology at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. "This unveiled significant associations between mutations, certain fundamental biological processes such as DNA repair and cell cycle, and identified key driver genes that will guide treatment and inform us of best therapies."

Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma

Daratumumab in combination with Pomalyst-dexamethasone and other traditional therapies has been shown to be safe and effective for patients with relapsed and/or refractory MM. "Our goal was to test the safety and tolerability of this combination," said Ajai Chari, MD, Associate Professor of Hematology and Medical Oncology and Director of Clinical Research in the Multiple Myeloma Program at TCI. "Patients had deep and durable response in a quick period of time, and the combination was well tolerated and did not result in any additional toxicity."

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Recent advances have improved outcomes for patients with multiple myeloma (MM); however, better therapies targeting new pathways are still needed. A multi-center research team evaluated 40 patients with MM who had received Ibrutinib (IBR), a once-daily Bruton's tyrosine kinase inhibitor that prevents both activation and signaling of B-cells, and observed that when combined with weekly dexamethasone yielded promising clinical potential and well tolerated by patients.

"The initial data has shown promising potential for this combination," said Dr. Chari. "Patients tolerated this combination and we believe it may positively regulate the myeloma stem cell-like population."
About the Mount Sinai Health System

The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services--from community-based facilities to tertiary and quaternary care.

The System includes approximately 6,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is ranked as one of the nation's top 10 hospitals in Geriatrics, Cardiology/Heart Surgery, and Gastroenterology, and is in the top 25 in five other specialties in the 2014-2015 "Best Hospitals" issue of U.S. News & World Report. Mount Sinai's Kravis Children's Hospital also is ranked in seven out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology, while Mount Sinai Beth Israel is ranked regionally.

For more information, visit or find Mount Sinai on Facebook, Twitter and YouTube.

The Mount Sinai Hospital / Mount Sinai School of Medicine

Related Multiple Myeloma Articles:

Study finds racial disparities in treatment of multiple myeloma patients
Among patients with multiple myeloma, African-Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances.
NEJM publishes bb2121 Phase 1 data in patients with multiple myeloma
Celgene Corporation and bluebird bio announce results from ongoing multicenter Phase 1 study of bb2121 anti-BCMA CAR T cell therapy in patients with multiple myeloma published in the New England Journal of Medicine.
Multiple myeloma: DNA rearrangement may predict poor outcomes
In multiple myeloma, Ig lambda translocations may indicate poor outcomes and resistance to immunomodulatory drugs such as lenalidomide.
Computational platform optimizes multiple myeloma treatments
Masturah Bte Mohd Abdul Rashid and colleagues have developed a new platform that optimizes drug combinations for the treatment of multiple myeloma (MM), an incurable blood cancer.
Screening high-risk individuals can reduce multiple myeloma mortality
Multiple myeloma is a rare incurable disease that is diagnosed in more than 30,000 people each year in the United States.
Carfilzomib can lead to cardiovascular toxicity in multiple myeloma patients
The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy comes with the risk of cardiovascular problems in a higher than expected percentage of patients.
Sequencing offers clues to progression toward multiple myeloma
Researchers at Dana-Farber Cancer Institute have carried out the largest genomic analysis of patients with smoldering multiple myeloma (SMM), a precursor to full-blown blood cancer that doesn't show outward symptoms.
Tracking how multiple myeloma evolves by sequencing DNA in the blood
Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back.
CAR T, immunotherapy bring new hope for multiple myeloma patients
Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other therapies.
In multiple myeloma, high levels of enzyme ADAR1 are associated with reduced survival
Using a database of multiple myeloma patient samples and information, researchers at University of California San Diego School of Medicine found that high ADAR1 levels correlate with reduced survival rates.
More Multiple Myeloma News and Multiple Myeloma Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Accessing Better Health
Essential health care is a right, not a privilege ... or is it? This hour, TED speakers explore how we can give everyone access to a healthier way of life, despite who you are or where you live. Guests include physician Raj Panjabi, former NYC health commissioner Mary Bassett, researcher Michael Hendryx, and neuroscientist Rachel Wurzman.
Now Playing: Science for the People

#544 Prosperity Without Growth
The societies we live in are organised around growth, objects, and driving forward a constantly expanding economy as benchmarks of success and prosperity. But this growing consumption at all costs is at odds with our understanding of what our planet can support. How do we lower the environmental impact of economic activity? How do we redefine success and prosperity separate from GDP, which politicians and governments have focused on for decades? We speak with ecological economist Tim Jackson, Professor of Sustainable Development at the University of Surrey, Director of the Centre for the Understanding of Sustainable Propserity, and author of...
Now Playing: Radiolab

An Announcement from Radiolab